SYMBICORT's oppositions filed in EPO
SYMBICORT Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6641800 | ASTRAZENECA | Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane |
Sep, 2012
(11 years ago) | |
| US5972919 | ASTRAZENECA | Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof |
Dec, 2012
(11 years ago) | |
| US5674860 | ASTRAZENECA | Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders |
Oct, 2014
(9 years ago) | |
| US6123924 | ASTRAZENECA | Pressurized aerosol inhalation compositions |
Sep, 2017
(6 years ago) | |
|
US6123924 (Pediatric) | ASTRAZENECA | Pressurized aerosol inhalation compositions |
Mar, 2018
(6 years ago) | |
| US8461211 | ASTRAZENECA | Use for budesonide and formoterol |
Sep, 2018
(5 years ago) | |
| US7897646 | ASTRAZENECA | Use for budesonide and formoterol |
Sep, 2018
(5 years ago) | |
| US7367333 | ASTRAZENECA | Inhalation device |
Nov, 2018
(5 years ago) | |
|
US8461211 (Pediatric) | ASTRAZENECA | Use for budesonide and formoterol |
Mar, 2019
(5 years ago) | |
|
US7897646 (Pediatric) | ASTRAZENECA | Use for budesonide and formoterol |
Mar, 2019
(5 years ago) | |
|
US7367333 (Pediatric) | ASTRAZENECA | Inhalation device |
May, 2019
(4 years ago) | |
| US7967011 | ASTRAZENECA | Inhalation device |
Aug, 2021
(2 years ago) | |
|
US7967011 (Pediatric) | ASTRAZENECA | Inhalation device |
Feb, 2022
(2 years ago) | |
| US11311558 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(1 year, 2 months ago) | |
| US10166247 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(1 year, 2 months ago) | |
| US8575137 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(1 year, 2 months ago) | |
| US7759328 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(1 year, 2 months ago) | |
| US8143239 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(1 year, 2 months ago) | |
|
US7759328 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(8 months ago) | |
|
US8575137 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(8 months ago) | |
|
US8143239 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(8 months ago) | |
|
US11311558 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(8 months ago) | |
|
US10166247 (Pediatric) | ASTRAZENECA | Composition for inhalation |
Jul, 2023
(8 months ago) | |
| US8875699 | ASTRAZENECA | Inhaler cap strap |
Nov, 2024
(6 months from now) | |
|
US8875699 (Pediatric) | ASTRAZENECA | Inhaler cap strap |
May, 2025
(1 year, 13 days from now) | |
| US7587988 | ASTRAZENECA | Inhaler device counter |
Apr, 2026
(1 year, 11 months from now) | |
|
US7587988 (Pediatric) | ASTRAZENECA | Inhaler device counter |
Oct, 2026
(2 years from now) | |
| US8387615 | ASTRAZENECA | Inhaler cap strap |
Mar, 2027
(2 years from now) | |
|
US8387615 (Pediatric) | ASTRAZENECA | Inhaler cap strap |
Sep, 2027
(3 years from now) | |
| US8528545 | ASTRAZENECA | Inhaler device that reduces the risk for miscounting a dosage |
Oct, 2028
(4 years from now) | |
| US8616196 | ASTRAZENECA | Inhalation device and a method for assembling said inhalation device |
Apr, 2029
(4 years from now) | |
|
US8528545 (Pediatric) | ASTRAZENECA | Inhaler device that reduces the risk for miscounting a dosage |
Apr, 2029
(4 years from now) | |
|
US8616196 (Pediatric) | ASTRAZENECA | Inhalation device and a method for assembling said inhalation device |
Oct, 2029
(5 years from now) | |
Symbicort is owned by Astrazeneca.
Symbicort contains Budesonide; Formoterol Fumarate Dihydrate.
Symbicort has a total of 33 drug patents out of which 23 drug patents have expired.
Expired drug patents of Symbicort are:
- US6641800
- US5972919
- US5674860
- US6123924
- US6123924*PED
- US8461211
- US7897646
- US7367333
- US8461211*PED
- US7897646*PED
- US7367333*PED
- US7967011
- US7967011*PED
- US11311558
- US10166247
- US8575137
- US7759328
- US8143239
- US7759328*PED
- US8575137*PED
- US8143239*PED
- US11311558*PED
- US10166247*PED
Symbicort was authorised for market use on 21 July, 2006.
Symbicort is available in aerosol, metered;inhalation dosage forms.
Symbicort can be used as use for maintenance treatment of chronic obstructive pulmonary disease, use for reducing exacerbations of chronic obstructive pulmonary disease, use for the treatment of chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema, use for the treatment of asthma.
The generics of Symbicort are possible to be released after 07 October, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-582) | Feb 27, 2012 |
| M(M-210) | Sep 11, 2020 |
| New Patient Population(NPP) | Jan 27, 2020 |
| M(M-214) | Dec 20, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
Drugs and Companies using
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient
Market Authorisation Date:
21 July, 2006Treatment:
Use for the treatment of asthma; Use for the treatment of chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema; Use for maintenance treatment of chronic obstructive...Dosage:
How can I launch a generic of SYMBICORT before its drug patent expiration?
More Information on Dosage
SYMBICORT family patents
